Conditions: Hypertension
Keywords: Nebivolol Bystolic TM Hypertension Stage 2 Hypertension
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 433
Healthy volunteers: no

Brief summary:
The primary object of this study is to evaluate the efficacy and safety of 6 weeks of nebivolol monotherapy compared with placebo in patients with systolic stage 2 hypertension.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Nebivolol intervention 2: Placebo
Intervention descriptions: intervention 1: 5 mg, titrated to 20 mg, once daily oral administration intervention 2: 5 mg or 20 mg once daily, oral administration

Protocol document: